Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTpximpact Hldg Regulatory News (TPX)

Share Price Information for Tpximpact Hldg (TPX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.50
Bid: 31.00
Ask: 34.00
Change: 0.00 (0.00%)
Spread: 3.00 (9.677%)
Open: 32.50
High: 32.50
Low: 32.50
Prev. Close: 32.50
TPX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Nudge Digital

1 Jul 2021 07:00

RNS Number : 7535D
Panoply Holdings PLC (The)
01 July 2021
 

This announcement contains inside information

1 July 2021

The Panoply Holdings PLC

("The Panoply", or the "Group")

 

Acquisition of Nudge Digital

The Panoply Holdings PLC, the technology-enabled services group focused on digital transformation, announces the acquisition of the entire issued and to be issued ordinary share capital of Nudge Digital Limited ("Nudge") (the "Acquisition"), a digital services agency which delivers strategy-led services primarily to the pharmaceutical industry, health sector and, more recently, to local authorities, with a particular focus around care pathways.

Bristol-based Nudge, founded in 2006 by CEO Luke Aikman, provides strategic consultancy and digital execution on mission-critical services, from global pharmaceutical projects to the software underpinning social housing and social care. Since its founding, Nudge has built up a strong client base including major pharmaceutical companies Roche and Galderma, private healthcare provider Bupa as well as the Greater London Authority, Hackney and Westminster councils.

The Acquisition is strategically important to the Group and strengthens its overall position in healthcare and, importantly, provides an entry into the pharmaceutical industry at a time when the NHS is looking at precision medicine, risk stratification and data-driven personalised care plans for patients.

The Acquisition is profitable and immediately earnings enhancing for The Panoply. Nudge has achieved significant revenue growth over the last two years of 151% and delivered revenues of £2.7m, adjusted EBITDA of £1.0m and adjusted profit after tax of £0.9m for the year ended 31 March 2021 (all unaudited). Nudge enters the group with a booked backlog of £2.5m for FY22.

The Panoply is paying a total consideration of £5.0m with £1.75m being satisfied in cash and £3.25m by the issue of new ordinary shares in The Panoply. The cash portion of the consideration will be funded through the Group's own cash reserves. The Group remains highly cash generative, with £4.9m net cash and a net debt position of £8.2m at 30 June, which remains at less than 1x pro forma EBITDA. 

 

Neal Gandhi, Chief Executive Officer of The Panoply, said:

"We're delighted to welcome Nudge to the Group at a time when the NHS is considering its approach to personalised healthcare and care pathways are coming into sharp focus as the government looks to deliver on its social care reform agenda.

Pulling together Nudge's experience in private healthcare and pharmaceuticals with the Group's existing experience across the NHS and local authority adult social care gives us a strong base to become a leader in the healthcare sector in the UK."

Luke Aikman, Chief Executive Officer of Nudge Digital, said:

"In recent months, Nudge has started to win contracts that are impactful and larger in size than ever before. By joining The Panoply, we can continue on that trajectory in the knowledge that we have a balance sheet that reassures our clients as well as a much larger team to draw upon to fulfill their requirements.

As a team, we're excited to begin working in collaboration with the rest of the Group and to continue delivering exceptional work to our client base."

 

Additional information on the acquisition

The Panoply has acquired all of the shares in Nudge Digital from Luke Aikman (CEO) and Jason Wilkes (Client Services Director).

The consideration payable under the share purchase agreement relating to the Acquisition (the "SPA") is £5m, subject to a completion accounts adjustment which is expected to result in the payment of approximately an additional £2.2m to Luke Aikman and Jason Wilkes in respect of excess cash in Nudge Digital. The consideration payable at completion of the Acquisition ("Completion") comprises the following:

(a) the allotment and issue of 1,190,476 new ordinary shares in The Panoply, with a value of £3.25m, calculated by reference to a price of 273 pence, being the 30 day average mid-market price on the day prior to announcement (the "Consideration Shares"); and

(b) a payment in cash of £1.75m.

together (the "Consideration").

The Consideration referred to in (b) above is being funded through the Group's existing cash reserves.

274,726 Consideration Shares or Consideration Shares with an aggregate value (based on the share price on the first anniversary of Completion) of £750,000 (whichever is higher) are released from lock-in on the first anniversary of Completion with the remainder of the Consideration Shares subject to lock-in arrangements until the third anniversary of Completion. Customary orderly market provisions apply for 12 months after each of the lock-in undertakings cease to apply.

Following the issue of the Consideration Shares, Luke Aikman and Jason Wilkes will hold 1,071,428 and 119,048 ordinary shares in The Panoply respectively, representing 1.4% in aggregate of the then issued share capital.

Admission and total voting rights

An application has been made for the admission of the Consideration Shares to trading on AIM which is expected to take place on or around 6 July 2021. Following this issue, the Company's issued share capital will comprise 82,571,502 Ordinary Shares and this is the total number of voting rights in the Company. There are no shares held in treasury.

This figure may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The person responsible for this announcement is Oliver Rigby, CFO.

Enquiries:

 

The Panoply Holdings

Neal Gandhi (CEO)

Oliver Rigby (CFO)

 

Stifel Nicolaus Europe Limited

(Nomad and Joint Broker)

 

Via Alma PR

 

 

+44 (0)207 710 7600

Fred Walsh

Alex Price

 

Dowgate Capital Limited

(Joint Broker)

James Serjeant

David Poutney

Nicholas Chambers

 

 

+44 (0)203 903 7715

Alma PR

(Financial PR)

Susie Hudson

Kieran Breheny

Matthew Young

panoply@almapr.co.uk

+44 (0)203 405 0209

 

About The Panoply

The Panoply is a technology-enabled services group, built to service clients' digital transformation needs. Founded in 2016, with the aim of identifying and acquiring best-of-breed specialist information technology, design and innovation consulting businesses, the Group collaborates with its clients to deliver the technology outcomes they're looking for at the pace that they expect and demand.

The Group is being increasingly recognised as a leading alternative digital transformation provider to the UK public services sector, with c.70% of its client base representing the public sector and c.30% representing the commercial sector.

More information is available at www.thepanoply.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQWPUUCQUPGPGU
Date   Source Headline
10th Apr 202412:25 pmRNSReplacement: Share Incentive Plan & TVR
10th Apr 20247:00 amRNSShare Incentive Plan & Total Voting Rights
8th Apr 20247:00 amRNSExercise of Options, PDMR Dealings & TVR
3rd Apr 20247:00 amRNSPDMR / PCA Shareholdings
13th Mar 20247:00 amRNSShare Incentive Plan & Total Voting Rights
7th Mar 20243:15 pmRNSHolding(s) in Company
13th Feb 20247:00 amRNSDirector Dealings, Transfer of EBT Shares & TVR
16th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSDirector/PDMR Shareholdings
10th Jan 20247:00 amRNSTransfer of shares from EBT & Total Voting Rights
9th Jan 202410:30 amRNSTPXimpact Certifies as a B Corporation
12th Dec 20237:00 amRNSTransfer of Shares from EBT & Total Voting Rights
8th Dec 20237:00 amRNSExercise of Options, PDMR Dealings & TVR
5th Dec 20237:00 amRNSInterim Results
10th Nov 20231:34 pmRNSTransfer of shares from EBT & Total Voting Rights
7th Nov 20237:00 amRNSNotice of Results and Presentations
16th Oct 20237:00 amRNSH1 Trading Update & Disposal of TPXimpact Norway
12th Oct 20237:00 amRNSTransfer of shares from EBT & Total Voting Rights
28th Sep 202311:00 amRNSResult of AGM
22nd Sep 20237:00 amRNSPDMR Dealings: Grant of share options to Group CEO
18th Sep 20237:00 amRNSSale of Questers for £7.5m
14th Sep 20237:00 amRNSTransfer of shares from EBT & Total Voting Rights
5th Sep 20231:05 pmRNSUpdate on Current Trading and Notice of AGM
25th Aug 20231:03 pmRNSHolding(s) in Company
11th Aug 20237:00 amRNSTransfer of shares from EBT & Total Voting Rights
20th Jul 20237:00 amRNSTransfer of Shares from EBT & Total Voting Rights
19th Jul 20233:15 pmRNSHolding(s) in Company
6th Jul 20237:00 amRNSPreliminary Results
30th Jun 20237:00 amRNSAgreement on Debt Covenants and Notice of Results
14th Jun 20237:00 amRNSTransfer of shares from EBT & Total Voting Rights
6th Jun 20237:00 amRNSIssue of Shares & Total Voting Rights
11th May 20237:00 amRNSTransfer of shares from EBT & Total Voting Rights
5th May 20237:00 amRNSTrading Statement
28th Apr 20232:35 pmRNSTotal Voting Rights
28th Apr 202310:18 amRNSContract wins
14th Apr 20235:27 pmRNSHolding(s) in Company Update
13th Apr 20237:00 amRNSTransfer of shares from EBT & Total Voting Rights
3rd Apr 20233:30 pmRNSTotal Voting Rights
31st Mar 20237:00 amRNSCovenant Waiver and Current Trading
9th Mar 20237:00 amRNSTransfer of Shares from EBT & Total Voting Rights
1st Mar 20237:00 amRNSTotal Voting Rights
24th Feb 20237:00 amRNSIssue of Shares
16th Feb 20237:00 amRNSLTIP, PDMR Dealings & Retention Award
10th Feb 20234:31 pmRNSTransfer of shares from EBT & Total Voting Rights
9th Feb 20237:00 amRNSHolding(s) in Company
8th Feb 202312:06 pmRNSHolding(s) in Company
3rd Feb 20231:54 pmRNSDirector/PDMR Shareholding
2nd Feb 20232:45 pmRNSHolding(s) in Company
2nd Feb 20232:40 pmRNSHolding(s) in Company
2nd Feb 20237:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.